Sperm without borders
This cross-border investigation examines how Europe’s fragmented sperm donation system creates regulatory blind spots that can have life-threatening consequences. In 2025, European health authorities confirmed that sperm from a Danish donor carrying a rare TP53 gene mutation linked to a high risk of cancer had been used to conceive at least 197 children across 14 countries. An international rapid alert was issued, yet the case revealed a deeper structural problem rather than an isolated failure. Sperm circulates freely across borders as part of an international market. Oversight, however, remains national. There is no EU-wide limit on how many families or children can be conceived from a single donor. There is no shared European database to track cumulative donor use. In many countries, comprehensive genetic testing panels are not mandatory, and risk assessment relies largely on self-reported medical histories combined with targeted screening. As a result, life-saving information may move slower than the cross-border trade itself. This investigation explores how regulatory gaps, limited data sharing, and inconsistent screening standards across Europe create systemic vulnerabilities.
English and German Version
The publication of the investigation in The European Correspondent’s English newsletter ensured that the story reached a broad European audience, including policymakers and researchers, placing the issue within a wider EU policy debate.
Its inclusion in the German newsletter was also significant, expanding the discussion within one of Europe’s key media and policy landscapes.
By circulating in both English and German, the investigation moved beyond a national case and entered a broader European conversation on genetic screening, donor limits, and cross-border oversight.
Click to read
Turkish Versions
The Turkish publication brought the risks created by Europe’s fragmented sperm donation system to a wider audience in Turkey. It highlighted how gaps in oversight and data sharing within a cross-border system can lead to global consequences.
Click to read on P24
Click to read on CancerDisinfo
About the investigation
Methodology
This investigation is based on cross-border reporting conducted between France, Belgium, Denmark, the Netherlands, and the United Kingdom. The reporting combined in-depth interviews, regulatory analysis, and document-based research.
I interviewed Families affected by genetic mutations, as well as representatives of sperm banks, national health authorities, ethics bodies, and policymakers. Expert perspectives included medical geneticists, reproductive health specialists, bioethics scholars, and government spokespersons.
The investigation relied on the analysis of national laws regulating sperm donation in multiple European countries, focusing on donor limits, genetic screening requirements, traceability mechanisms, and cross-border data sharing practices. Official written responses were obtained from relevant institutions, including sperm banks and health ministries.
Conference presentations, preliminary scientific data, and public regulatory documents were reviewed to reconstruct the timeline of the TP53 case and assess systemic gaps. Where possible, claims were cross-checked against regulatory texts and official statements.
Particular attention was given to identifying structural vulnerabilities rather than isolated failures, examining how inconsistencies between national systems create risks in an increasingly cross-border reproductive market.
Funding
This investigation was produced with the support of the Balkan Investigative Reporting Network (BIRN).
Impact
This investigation has contributed to growing public debate on the safety and oversight of cross-border sperm donation in Europe. By exposing regulatory fragmentation, gaps in genetic screening, and the absence of EU-wide donor limits, the story reframed what was initially perceived as an isolated medical case into a structural governance issue.
Seda Karatabanoglu 